Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2002-01-25
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.3s-guojian.com
A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
- Conditions
- Acute Gout
- Interventions
- Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mgOther: Placebo
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-14
- Target Recruit Count
- 500
- Registration Number
- NCT06169891
Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: 611 450 mg Q2WDrug: Matching placeboDrug: 611 300 mg Q2W
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 150
- Registration Number
- NCT06099652
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
The MAD Study of SSGJ-613 in Healthy Subjects
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Target Recruit Count
- 36
- Registration Number
- NCT05966701
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- SinusitisNasal PolypsPolyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-01-12
- Target Recruit Count
- 90
- Registration Number
- NCT05865496
- Locations
- 🇨🇳
Site 03, Beijing, Beijing, China
🇨🇳Site 01, Beijing, Beijing, China
🇨🇳Site 04, Wuhan, Hubei, China
Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: 611 150mgDrug: 611 300mgDrug: 611 600mgOther: Placebo
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2022-12-07
- Target Recruit Count
- 24
- Registration Number
- NCT05641558
- Locations
- 🇨🇳
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳Nanyang First People's Hospital, Nanyang, Henan, China
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: Recombinant Anti-IL-17A Humanized Monoclonal Antibody InjectionOther: Placebo
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2022-11-08
- Target Recruit Count
- 139
- Registration Number
- NCT05604898
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
🇨🇳Shanghai Dermatology Hospital, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
- Conditions
- Acute Gout
- Interventions
- Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)Other: Placebo (phase II)
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2022-10-20
- Target Recruit Count
- 120
- Registration Number
- NCT05588908
- Locations
- 🇨🇳
Site 02, Wuhan, Hubei, China
🇨🇳Site 03, Linyi, Shandong, China
🇨🇳Site 01, Shanghai, Shanghai, China
A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- Conditions
- Asthma
- Interventions
- Drug: 610 30mg groupDrug: 610 100mg groupDrug: 610 300mg groupOther: Placebo 30mg groupOther: Placebo 100mg groupOther: Placebo 300mg group
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2022-10-18
- Target Recruit Count
- 24
- Registration Number
- NCT05584306
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 93
- Registration Number
- NCT05544591
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, China
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: 608 Q4WDrug: 608 Q2WDrug: Placebo
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 458
- Registration Number
- NCT05536726
- Locations
- 🇨🇳
Shanghai Huanshan Hospital Fudan University, Shanghai, Shanghai, China